Evelo Biosciences Inc. is a clinical-stage biotechnology company focused on the development of orally delivered medicines that target immune cells in the small intestine to drive systemic therapeutic effects. Its research centers on what it identifies as the small intestinal axis (SINTAX), a network that connects the immune responses in the gut to the rest of the body. By leveraging this pathway, Evelo aims to develop drug candidates that can modulate immune responses broadly, impacting the treatment of inflammatory diseases and certain cancers. The company’s pipeline features investigational products utilizing specific single strains of commensal microbes or their extracellular vesicles, with its lead candidate targeting inflammatory conditions including the hyperinflammatory response associated with COVID-19. Based in Cambridge, Massachusetts, Evelo Biosciences plays a notable role in advancing immunology and microbiome science within the biotechnology sector, offering a unique approach to systemic disease intervention through oral therapeutics.